Andrew Paul Mazar

Insider Reports History

Entity
Individual
Location
1000 Skokie Blvd, Suite 350, Wilmette, IL
Signature
/s/ Paul Lytle, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Andrew Paul Mazar:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Monopar Therapeutics Chief Scientific Officer, Director Common Stock 167K $56.7K $0.34 Mar 31, 2022 Indirect
Monopar Therapeutics Chief Scientific Officer, Director Restricted Stock Units 88.8K $30.2K $0.34 Mar 31, 2022 Direct
Monopar Therapeutics Chief Scientific Officer, Director Common Stock 22.1K $7.53K $0.34 Mar 31, 2022 Direct
ACTUATE THERAPEUTICS, INC. Chief Operating Officer Common Stock 127K Aug 12, 2024 Direct

Insider Reports Filed by Andrew Paul Mazar

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ACTU ACTUATE THERAPEUTICS, INC. Aug 12, 2024 0 $0 3 Aug 12, 2024 Chief Operating Officer
MNPR Monopar Therapeutics Mar 31, 2022 3 -$1.2K 4 Apr 1, 2022 Chief Scientific Officer, Director
MNPR Monopar Therapeutics Feb 2, 2022 2 $0 4 Feb 4, 2022 Chief Scientific Officer, Director
MNPR Monopar Therapeutics Jan 1, 2022 3 -$2.15K 4 Jan 4, 2022 Chief Scientific Officer, Director
MNPR Monopar Therapeutics Dec 31, 2021 3 -$1.78K 4 Jan 4, 2022 Chief Scientific Officer, Director
MNPR Monopar Therapeutics Sep 30, 2021 3 -$2.29K 4 Oct 1, 2021 Chief Scientific Officer, Director
MNPR Monopar Therapeutics Jun 30, 2021 3 -$5.55K 4 Jul 2, 2021 Chief Scientific Officer, Director